Decrease of tumoral CD39+CD8+T cells promoted by hypoxia confers resistance to immunotherapy in NSCLC
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Understanding resistance to anti-PD-1 is crucial for the development of reversal strategies. Here, we analyzed a subset of tumor-infiltrating CD8 + T cells based on the expression of the ATP ectonucleotidase CD39, further explored its spatial distribution being priming as a contributor to anti-PD-1 therapeutic response or resistance. It is interesting that CD39 + CD8 + T cells were more enriched in peritumor compared to center, as well as being severed as a potential immuno-responsive biomarker for anti-PD-1 therapy. Correspondingly, it revealed more hypoxia actually existed in central TME, thereby reducing CD39 + CD8 + T cells infiltration and dampening the efficacy of anti-PD-1. As supported, multiple in vitro assays demonstrated that absence of CD39 limited functional restore of CD8 + T cells upon PD-1 blockade. Collectively, we illustrated the hypoxia was involved in establishing an immunosuppressive TME defined by spatial distribution of CD39 + CD8 + T cells and consequentially implied a novel approach of resistance to immunotherapy.
